Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0151744 (myocardial ischemia)
 31,282 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Therapeutic strategy for ischemic heart disease has been changing in this decade. We attempted to improve the conventional extracorporeal circulation with the aim of less invasive coronary artery revascularization. Our extracorporeal circulation has been used since 2002, and called the 'mini-pump system' or 'MECC (minimized extracorporeal circulation) system'. The mini-pump system has a centrifugal pump, a membrane oxygenator, a soft reservoir and the characteristics of low prime volume completely closed circuit and low volume cardioplegia. We investigated the degree of invasiveness of the mini-pump system by examining the clinical outcomes (minimum hematocrit, the amount of transfusion and so on), thrombin-antithrombin III complex (TAT), complement factor (C3a) and interleukin (IL)-10 levels. The mini-pump system demonstrated better value than the conventional extracorporeal circulation (TAT; 19.5 : 66.1 ng/ml, C3a; 1,349 : 1,895 mg/dl, IL-10; 105 : 486 pg/ml, respectively) and proved to be less invasive. The incidence of postoperative atrial fibrillation using the mini-pump system was less than that of the conventional extracorporeal circulation. In this issue we presented the vista of the mini-pump system by showing how it decreased invasiveness.
 ...
PMID:[Arrested coronary artery bypass grafting with modified percutaneous cardiopulmonary support circuit (mini-pump system)]. 1691 May 5

To understand the heterogeneity of platelets, we investigated the correlation between hemostatic factors and the platelet index [platelet count, mean platelet volume (MPV), platelet-large cell ratio (P-LCR) and platelet distribution width (PDW)] in patients with ischemic heart disease (IHD). Ninety-seven patients with IHD and 120 aged controls (AC) were enrolled in the study. D-dimer, thrombin-antithrombin III complex (TAT), von Willebrand factor antigen (VWF:Ag) and platelet indexes were measured in the peripheral venous blood. The D-dimer and TAT levels in the patients were significantly elevated compared to the AC. VWF:Ag was also elevated, but not significantly so. However, no differences were observed in the platelet index between the patients and the AC. In the patients, the level of VWF:Ag was significantly inversely correlated with the platelet count, but such correlations were not observed in the D-dimer and TAT. TAT was significantly positively correlated with MPV, P-LCR and PDW. VWF:Ag was also correlated, though not significantly, with MPV, P-LCR and PDW. The D-dimer was not correlated with the platelet index. In the AC, the platelet count was inversely correlated with VWF:Ag, but not significantly so. VWF:Ag showed significant positive correlations with MPV, P-LCR and PDW. However, the D-dimer and TAT were not correlated with the platelet index in AC. These findings suggest that VWF:Ag and TAT seem to be profoundly related to platelet volume.
 ...
PMID:Relationship between hemostatic factors and the platelet index in patients with ischemic heart disease. 1723 41

The deadliest manifestations of ischemic heart disease are initiated and propagated by intra-coronary thrombin generation. Thrombin is resistant to inactivation by heparin when it is bound to fibrin, fibrin degradation products or subendothelial collagen. Recognition of these limitations has led to development of a new class of antithrombin agents which directly target the active sites on the surface of thrombin molecule and are therefore designated as direct antithrombins. These agents do not need mediation of antithrombin III for their action and are not inhibited by platelet factor 4. This report focuses on bivalirudin, a new agent of promising impact on both interventional as well as non-interventional cardiology. It is a short acting anticoagulant which bivalently and directly inhibits thrombin (coagulation factor II). It binds the active (catalytic) site and the fibrinogen-binding site (exosite I). This provides high affinity and specificity for thrombin. Slow cleavage at the Arg3-Pro4 bond results in recovery of thrombin activity after discontinuation of bivalirudin. Bivalirudin inhibits both protease activated receptor 1 and 4 (PAR 1 and PAR 4) thereby effectively inhibiting acute thrombin mediated platelet aggregation. Clinical efficacy has been assessed and proved in over 20 published patient series focussing on patients with acute coronary syndrome with or without myocardial infarction, patients undergoing percutaneous coronary interventions, patients receiving various adjunctive anti-platelet medications, patients with heparin induced thrombocytopenia or patients undergoing cardiac surgery. In contrast to the well established unfractionated heparin, bivalirudin lacks the risk of heparin induced thrombocytopenia. It shows a tendency to lower bleeding risks without reduction of efficacy when compared with the two-pronged treatment with unfractionated heparin and glycoprotein IIb/IIIa inhibitors.
 ...
PMID:Bivalirudin: a new promising direct antithrombin. 1912 43

Levels of fatty acids in platelets of ischemic heart disease (IHD) patients (n = 39) has been compared with those in healthy subjects (n = 12). Increased content of arachidonic acid and thromboxane A2 in platelets of IHD patients forms thrombogenic picture of IHD. High level of fibrinogen and decrease in heparin and antithrombin III in IHD patients facilitates formation of blood clots. Morphological examination of platelets in IHD patients has demonstrated an increase of levels of discocytes and spherocytes as well as appearance of small and large platelet-erythrocyte aggregates promoting blood slot formation.
 ...
PMID:[Dynamics of morphological structures of platelets in patients with ischemic heart disease in dependence on blood levels of fatty acids]. 2162 99

Interrelation between fatty acids and platelet aggregation has been a subject of interest for cardiologists in the terms of thrombogenic status. In order to study this problem we observed 42 patients with ischemic heart disease and 30 healthy persons. In patients we found elevation of arachidonic acid and lowering of docosahexaenic acid levels. Hypoxemic assay revealed in these patients lowering of prostacyclin and antithrombin III levels. In the pathogenesis of disturbances of platelet aggregation in patients with ischemic heart disease alteration of structure of platelets with increased quantity of phosphatidyl ethanolamine and corresponding change of thrombocyte asymmetry resulted in conformational reorganization of proteins and lipids.
...
PMID:[Value of Fatty acids in formation of thrombotic status in patients with ischemic heart disease]. 2517 82

Fondaparinux is a synthetic heparin pentasaccharide with a sequence identical to that found in anticoagulant heparin. It is a pure compound with a molecular weight of 1728Da. Fondaparinux catalyzes the conformational change of a serpin or serine protease inhibitor antithrombin III to accelerate the suicidal inactivation of factor Xa over 340-fold, which in turn inhibits thrombin generation in the coagulating signal transduction pathway. Fondaparinux does not inhibit thrombin activity, release tissue factor pathway inhibitor, or possess other properties of heparin such as anti-inflammatory, anti-viral, anti-angiogenesis, anti-neoplastic, and anti-metastatic effects though high affinity interactions with a variety of proteases, protease inhibitors, chemokines, cytokines, growth factors, and their respective receptors. Low antithrombin III levels in blood circulation also affects the efficacy of Fondaparinux. Thus, Fondaparinux represents a refined use of the anti-factor Xa property of heparin. As an anti-factor Xa drug, Fondaparinux has complete bioavailability subcutaneously, instant onset of action, a half-life of 15-20h, and a direct renal excretion without any metabolism. Fondaparinux has been shown to be superior to low molecular weight heparin in preventing deep vein thrombosis. Clinically, Fondaparinux is used for the prevention of deep vein thrombosis in patients who have had orthopedic surgery as well as for the treatment of deep vein thrombosis and pulmonary embolism with limitations of use in elderly, low weight, renal impaired patients and in those receiving spinal anesthesia. Clinical studies showed that Fondaparinux acts in prevention and treatment of venous thromboembolism and in ischemic heart disease without significant risk of bleeding.
 ...
PMID:The clinical use of Fondaparinux: A synthetic heparin pentasaccharide. 3103 Jul 56


<< Previous 1 2 3 4